

# Philippe L Bedard

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5636220/philippe-l-bedard-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176  
papers

7,358  
citations

45  
h-index

82  
g-index

195  
ext. papers

9,337  
ext. citations

7.1  
avg, IF

5.92  
L-index

#	Paper	IF	Citations
176	Tumour heterogeneity in the clinic. <i>Nature</i> , <b>2013</b> , 501, 355-64	50.4	770
175	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 597-609	59.2	396
174	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , <b>2018</b> , 563, 579-583	50.4	344
173	The genetic basis for cancer treatment decisions. <i>Cell</i> , <b>2012</b> , 148, 409-20	56.2	242
172	Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1341-51	12.9	239
171	Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt319	9.7	216
170	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 730-8	12.9	215
169	Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 51-7	2.2	193
168	AKT Inhibition in Solid Tumors With AKT1 Mutations. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2251-2259	2.2	184
167	International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1174-81	9.7	177
166	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2804-2811	12.9	167
165	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , <b>2016</b> , 8, 109	14.4	149
164	Luminal-B breast cancer and novel therapeutic targets. <i>Breast Cancer Research</i> , <b>2011</b> , 13, 221	8.3	142
163	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1824-1829	10.3	139
162	Cancer genomics: technology, discovery, and translation. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 647-60	2.2	134
161	Neratinib Efficacy and Circulating Tumor DNA Detection of Mutations in Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5687-5695	12.9	119
160	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , <b>2020</b> , 395, 1078-1088	40	107

159	Ocular toxicity of targeted therapies. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3277-86	2.2	95
158	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.. <i>Nature Cancer</i> , <b>2020</b> , 1, 873-881	15.4	89
157	Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 22-36	19.4	87
156	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 1100-7	4.3	85
155	Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?. <i>Targeted Oncology</i> , <b>2009</b> , 4, 77-88	5	83
154	A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2020</b> , 43, 484-490	2.7	82
153	Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , <b>2014</b> , 22, 391-5	5.3	79
152	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , <b>2019</b> , 125, 1341-1349	6.4	78
151	A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in -Mutated Breast and Gynecologic Cancers. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2050-2059	12.9	74
150	Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 1547-55	7.5	73
149	Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. <i>Cancer Discovery</i> , <b>2014</b> , 4, 527-37	24.4	67
148	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , <b>2016</b> , 18, 128-36	8.1	66
147	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , <b>2018</b> , 200, 126-135	2.5	65
146	Enhancing reproducibility in cancer drug screening: how do we move forward?. <i>Cancer Research</i> , <b>2014</b> , 74, 4016-23	10.1	64
145	Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4260-7	2.2	64
144	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , <b>2014</b> , 32, 243-9	4.3	63
143	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. <i>Neurology</i> , <b>2020</b> , 94, 481-494	6.5	60
142	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	60

141	A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). <i>British Journal of Cancer</i> , <b>2013</b> , 109, 943-9	8.7	59
140	Genomic testing in cancer: patient knowledge, attitudes, and expectations. <i>Cancer</i> , <b>2014</b> , 120, 3066-73	6.4	58
139	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1065-71	2.2	56
138	Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1788-93	8.7	56
137	Testicular cancer survivors: supportive care needs and use of online support: a cross-sectional survey. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2737-46	3.9	53
136	Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3482-7	2.2	53
135	Stemming resistance to HER-2 targeted therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , <b>2009</b> , 14, 55-66	2.4	52
134	Ocular toxicities of MEK inhibitors and other targeted therapies. <i>Annals of Oncology</i> , <b>2016</b> , 27, 998-1005	10.3	51
133	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , <b>2012</b> , 13, e240-8	21.7	51
132	A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 740-749	4.3	45
131	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1182-91	4.3	45
130	Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. <i>Current Cancer Drug Targets</i> , <b>2009</b> , 9, 148-62	2.8	44
129	Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 582-7	2.2	42
128	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4380-4387	12.9	41
127	Identification of genomic signatures in circulating tumor cells from breast cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 332-44	7.5	39
126	Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 108, 307-17	4.4	39
125	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 1269-77	4.3	38
124	The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 1915-1922	3.9	37

123	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1348-55	12.9	37
122	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , <b>2017</b> , 71, 120-127	10.2	34
121	Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 100-6	2.2	34
120	Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. <i>Critical Reviews in Oncology/Hematology</i> , <b>2010</b> , 75, 110-21	7	33
119	Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. <i>Oncologist</i> , <b>2020</b> , 25, e160-e169	5.7	31
118	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1558-1562	13.4	29
117	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1919-1926	2.2	29
116	Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer. <i>Value in Health</i> , <b>2013</b> , 16, 729-39	3.3	29
115	Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. <i>Clinical Breast Cancer</i> , <b>2008</b> , 8 Suppl 4, S157-65	3	27
114	Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 714-20	2.2	26
113	Quality of life and understanding of disease status among cancer patients of different ethnic origin. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 641-7	8.7	26
112	A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 650-9	8.7	25
111	Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy. <i>Journal of Oncology</i> , <b>2015</b> , 2015, 609194	4.5	25
110	Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 272-9	19.4	25
109	mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 346-352	3.5	21
108	First-in-human trial of the PI3K-selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , <b>2018</b> , 124, 315-324	6.4	21
107	Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?. <i>BMC Cancer</i> , <b>2011</b> , 11, 426	4.8	21
106	A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 520-520	2.2	20

105	Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). <i>Gynecologic Oncology</i> , <b>2017</b> , 144, 250-255	4.9	19
104	Characteristics and Outcome of -Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , <b>2020</b> , 10, 526-535	24.4	19
103	Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 354-363	12.9	19
102	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 159-168	4.4	19
101	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. <i>Journal of Urology</i> , <b>2015</b> , 194, 386-91	2.5	18
100	Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 318-324	8.7	18
99	Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3620-3629 <sup>18</sup>	12.9	18
98	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 261-273	5.1	17
97	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) <b>2019</b> , 7, 72		16
96	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 73-79	3.8	16
95	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1162-8	21.7	15
94	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , <b>2018</b> , 4, 995-1001	5.1	14
93	A phase Ib, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3003-3003	2.2	14
92	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , <b>2019</b> , 24, e146-e148	5.7	14
91	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI?9041). <i>Investigational New Drugs</i> , <b>2016</b> , 34, 104-11	4.3	13
90	Modifying phase I methodology to facilitate enrolment of molecularly selected patients. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1515-20	7.5	13
89	Clinical genomics information management software linking cancer genome sequence and clinical decisions. <i>Genomics</i> , <b>2013</b> , 102, 140-7	4.3	13
88	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R97	8.3	13

87	Therapeutic management of breast cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 945-60	4	13
86	Benefits and harms of detecting clinically occult breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1542-7	9.7	13
85	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with -Mutant Cancers. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 447-459	12.9	13
84	American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions Perspectives. <i>JCO Clinical Cancer Informatics</i> , <b>2018</b> , 2, 1-14	5.2	13
83	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , <b>2018</b> , 11, 65	3.7	12
82	Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). <i>PLoS ONE</i> , <b>2010</b> , 5, e121007	10.7	12
81	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors <b>2020</b> , 8,		12
80	Management of small HER2 overexpressing tumours. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 136, 289-93	4.4	11
79	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 221-230	5.2	11
78	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , <b>2021</b> , 4, 483-491	6.7	11
77	Outcome Definition Influences the Relationship Between Genetic Polymorphisms of , , and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. <i>Genes</i> , <b>2019</b> , 10,	4.2	10
76	Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4043-6	2.2	10
75	Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 516-516	2.2	10
74	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2796-2811	24.4	10
73	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 192-198	9.7	10
72	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , <b>2018</b> , 2, 1-12	5.2	10
71	MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. <i>Expert Opinion on Medical Diagnostics</i> , <b>2009</b> , 3, 193-205		9
70	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , <b>2020</b> , 126, 1550-1558	6.4	9

69	Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). <i>Cancer Medicine</i> , <b>2020</b> , 9, 116-124	4.8	9
68	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, 204-209	1.2	9
67	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, 59-66	1.2	8
66	Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. <i>Breast Cancer Research</i> , <b>2009</b> , 11, 201	8.3	8
65	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11002-11002	2.2	8
64	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. <i>European Urology Oncology</i> , <b>2019</b> , 2, 437-442	6.7	8
63	A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1539-1544	3.4	7
62	Stage II seminomas and nonseminomas. <i>Hematology/Oncology Clinics of North America</i> , <b>2011</b> , 25, 529-413, viii	3.4	7
61	Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 779-786	2.2	7
60	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 980-988	9.7	7
59	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 3015-3022	4.8	6
58	Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians. <i>Molecular and Clinical Oncology</i> , <b>2018</b> , 8, 153-158	1.6	6
57	Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. <i>Investigational New Drugs</i> , <b>2017</b> , 35, 827-833	4.3	6
56	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, 721-30	5.7	6
55	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , <b>2021</b> , 11, 822-837	24.4	6
54	Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 106-115	7.1	5
53	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	5
52	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa122	4.6	5



51	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , <b>2021</b> , 12, 5137	17.4	5
50	Latency and interval therapy affect the evolution in metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 581	4.9	4
49	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 121-133	4.4	4
48	Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. <i>Journal of Clinical Pathology</i> , <b>2015</b> , 68, 839-43	3.9	4
47	Personalized medicine for metastatic breast cancer. <i>Current Opinion in Oncology</i> , <b>2013</b> , 25, 615-24	4.2	4
46	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , <b>2016</b> , 2, a001016	2.8	3
45	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , <b>2018</b> , 122, 814-822	5.6	3
44	Anterior transpericardial approach for postchemotherapy residual midvisceral mediastinal mass in metastatic germ cell tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2013</b> , 145, 1136-1138	1.5	3
43	The role of capecitabine in the management of breast cancer in elderly patients. <i>Journal of Geriatric Oncology</i> , <b>2011</b> , 2, 72-81	3.6	3
42	Spinal cord stimulators and radiotherapy: first case report and practice guidelines. <i>Radiation Oncology</i> , <b>2011</b> , 6, 143	4.2	3
41	Molecular Biology of Breast Cancer <b>2010</b> , 341-349		3
40	Aiming at the target: improved adjuvant medical therapy. <i>Breast</i> , <b>2009</b> , 18 Suppl 3, S25-30	3.6	3
39	Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. <i>Current Opinion in Oncology</i> , <b>2009</b> , 21, 491-8	4.2	3
38	A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2500-2500	2.2	3
37	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2542-2542	2.2	3
36	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , <b>2020</b> , 28, 107-114	2.8	3
35	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa115	4.6	3
34	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , <b>2021</b> , 7, 1130-1136	5.1	3

33	Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2021</b> , 161, 856-868.e1	1.5	3
32	Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , <b>2021</b> , 10, 940-949	2.3	3
31	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz071	4.6	2
30	Decoding the evolution of a breast cancer genome. <i>EMBO Molecular Medicine</i> , <b>2010</b> , 2, 3-5	12	2
29	Nonhormonal systemic therapy for advanced breast cancer: do the math!. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 1745-7	9.7	2
28	A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3082-3082	2.2	2
27	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1532-1532	2.2	2
26	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , <b>2020</b> , 9, 337	3.6	2
25	Novel classes of immunotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 1	4.4	2
24	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	2
23	Delivery of chemotherapy for testicular cancer in routine practice: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 183.e17-183.e24	2.8	2
22	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , <b>2021</b> , 4, 289-296	6.7	2
21	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2117547	10.4	2
20	OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing. <i>Current Oncology</i> , <b>2019</b> , 26, e618-e623	2.8	1
19	MP10-10 OUTCOMES OF PROGRESSION ON SURVEILLANCE FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMOURS. <i>Journal of Urology</i> , <b>2015</b> , 193,	2.5	1
18	Molecular Biology of Breast Cancer <b>2009</b> , 501-517		1
17	Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria.. <i>European Heart Journal - Case Reports</i> , <b>2022</b> , 6, ytab478	0.9	1
16	Clinical dilemmas in local and regional testis cancer. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E58-E64	1.2	1

15	Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. <i>Canadian Urological Association Journal</i> , <b>2021</b> ,	1.2	1
14	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.. <i>Cancer Medicine</i> , <b>2021</b> ,	4.8	1
13	No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	1
12	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E537-E542	1.2	0
11	A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach.. <i>JCO Clinical Cancer Informatics</i> , <b>2022</b> , 6, e2100105	5.2	0
10	Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. <i>European Urology Open Science</i> , <b>2022</b> , 40, 46-53	0.9	0
9	A Canadian approach to the regionalization of testis cancer: A review. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, 346-351	1.2	
8	Doubling back on centromere 17 in early breast cancer. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 216-7	21.7	
7	IDH-1/2 mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23210-e23210	2.2	
6	P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5550-5550	2.2	
5	Comparison of genotype-specific progression free survival (PFS) outcomes in the control (ctrl) arms of randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2536-2536	2.2	
4	Large retroperitoneal lymph nodes (RPLN) as a novel risk factor for venous thromboembolism (VTE) in germ cell tumor (GCT) patients (pts) receiving first-line chemotherapy (chemo).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4535-4535	2.2	
3	Randomized controlled trials in testicular cancer: A demographic and quality assessment. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 60.e7-13	2.8	
2	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , <b>2019</b> , 24, e518-e525	5.7	
1	Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies.. <i>JCO Precision Oncology</i> , <b>2018</b> , 2, 1-20	3.6	